Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
PER.C6® 细胞系生产的 3 种 Sabin 灭活脊髓灰质炎病毒疫苗配方的安全性和免疫原性：对 6、10 和 14 周龄接种疫苗的婴儿进行的一项 2 期双盲随机对照研究
期刊:Human Vaccines & Immunotherapeutics
影响因子:
doi:10.1080/21645515.2022.2044255
Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P Cahill, Hanneke Schuitemaker, Macaya Douoguih, Jeanne-Marie Jacquet
